GlaxoSmithKline (GSK) has initiated its second large-scale Phase III clinical trial with experimental heart drug darapladib as a treatment for clogged arteries.

The latest trial will evaluate the investigational Lp-PLA inhibitor darapladib in men and women with acute coronary syndrome.

GSK will carry out the study in 11,500 patients from 40 countries, bringing the total number of subjects in the combined clinical trial programme to more than 27,000.

The study will determine whether darapladib affects the chances of having a cardiovascular event, such as a heart attack or stroke.